CDF-Capital
VC Fund
Shenzhen, China
CDF-Capital is a private equity firm invests in growth and early-stage companies and its business covers 3+1 investment, including equity investment (start-up investment, M&A investment, industrial investment) and incubation investment (Chuangzhan Incubator). Since its establishment, it has received funding and recognition from the StateMinistry (Ministry of Finance, Ministry of Science and Technology), government guidance funds, parent funds, banks, and insurance companies.
- Total investments:
- 89
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries CDF-Capital invests in
Stages CDF-Capital invests in
Countries CDF-Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $227k–$148M
- Series A
- $206k–$16M
- Series B
- $424k–$46M
Investment Focus
Industry
- Manufacturing 21 (24%)
- Software 9 (10%)
- Information Technology 8 (9%)
- Health Care 7 (8%)
- Semiconductor 7 (8%)
Stage
- Series A 30 (34%)
- Series B 23 (26%)
- Seed 14 (16%)
- Angel 8 (9%)
- Series C 7 (8%)
Country
- China 78 (88%)
- United States 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Xiao Shuilong
Chairman & Founding Partner
|
Chairman & Founding Partner | Total investments: 0 | Find email | |
|
Ruan Qingguo
Managing Partner and President
|
Managing Partner and President | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Barty Medical
|
Barty Medical develops, manufactures, and markets coronary drug balloons, peripheral drug balloons, coronary PTCA balloons, peripheral PTA balloons, peripheral drug stents, supporting catheter sheaths, vascular interventional devices, and implanted devices. | $29.5M / Series D / Jun 10, 2026 | |
|
Xingyuanzhi Robotics
|
Xingyuanzhi Robotics strives to develop multimodal spatial intelligence systems and a universal embodied brain capable of comprehending and interacting with the physical world. | $147.8M / Seed / Jun 03, 2026 | |
Shitian Technology
|
Shitian Technology is a chemical enterprise that manufactures modified plastic compounds. The business operates in industrial sectors by supplying plastic components used for automotive interior and exterior parts, along with materials for electronic devices. | Venture - Series Unknown / May 22, 2026 | |
ZeroErr Co., Ltd.
|
ZeroErr specializes in the design, development, and manufacturing of rotary actuators and encoders, embodying a commitment to flawless motion control solutions. Our mission is to create reliable physical components that bridge the gap between digital innovation and physical implementation, ensuring high-quality products for a global clientele. Weenvision transforming laborious physical work into digital control to enhance efficiency, precision, and safety across various industries, including automation, collaborative, surgical, and humanoid robotics. Driven by this mission, we provide high-quality, cost-effective solutions and responsive technical support, enabling our customers to achieve exceptional application performance and setting industry standards in motion control.- Industries Served: - Automation； - Collaborative Robotics； - Surgical Robotics； - Humanoid Robotics. - Our Offerings: - High-Quality Solutions: Ensuring reliability and peak performance - Cost-Effective Products: Delivering value without compromising quality - Responsive Technical Support: Empowering our customers with the assistance they need to drive innovation and enhance productivityFor more information, visit our | Series C / Mar 02, 2026 | |
|
Zhuopu Microelectronics
|
Zhuopu Microelectronics offers integrated testing technology in the semiconductor and materials fields. | Seed / Dec 25, 2025 | |
Jindu Biotechnology
|
Jindu Biosciences is a global leader at the intersection of artificial intelligence and life sciences. The company is dedicated to advancing biological research by integrating cutting-edge AI technologies with bioinformatics and multi-omics data analysis. Their mission is to accelerate the life sciences field into a new era dominated by pre-trainedAI models, enabling faster, more accurate biological discoveries and innovations. | Seed / Oct 24, 2025 | |
Aowei Linkcore
|
Aowei Linkcore specializes in the designing, development, production, and sales of high-performance RISC-V processor chips. | Seed / Aug 26, 2025 | |
|
Tsinghua Huahe
|
Tsinghua Huahe is a medical devices company that provides research and development of modified PEEK materials. | Seed / Jul 08, 2025 | |
Coreview
|
Coreview is an OLED developer, focusing on silicon-based OLED IC design and silicon-based OLED microdisplay R&D and manufacturing. | $83.5M / Seed / Jun 17, 2025 | |
U-Magnetics Technology
|
U-Magnetics Technology is a general equipment manufacturer that specializes in the creation of high-flux power systems, which include switching reluctance motors, novel high-permeability materials, and new DC servo control systems. | $4.1M / Series A / Dec 19, 2024 | |
| See all 89 investments → | |||
Co-Investors
CDH Investments
3 deals together
Cowin Capital
3 deals together
Fortune Venture Capital
3 deals together
Caifu SenLin
2 deals together
CASH Capital
2 deals together
CAS Star
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does CDF-Capital invest in?
CDF-Capital invests primarily in Manufacturing, Software and Information Technology startups, most often at Series A and Series B stage. Most of the 89 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is CDF-Capital's check size?
CDF-Capital typically joins rounds of $227k–$148M at Seed, $206k–$16M at Series A and $424k–$46M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds CDF-Capital participates in.
How do I contact CDF-Capital?
Public channels for CDF-Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CDF-Capital?
The team at CDF-Capital includes Xiao Shuilong (Chairman & Founding Partner) and Ruan Qingguo (Managing Partner and President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
